RESUMO
Regimens for the treatment of rifampicin-resistant tuberculosis currently rely on the use of QT-prolonging agents. Using data from the randomized controlled trial, TB-PRACTECAL, we investigated differences in QTcF among participants in the three interventional arms: BPaL (bedaquiline, pretomanid, and linezolid), BPaLC (BPaL with clofazimine), and BPaLM (BPaL with moxifloxacin). Additionally, we assessed whether age, body mass index, and country were causally associated with QTcF prolongation. The trial included participants from South Africa, Uzbekistan, and Belarus. A post hoc analysis of electrocardiogram data was undertaken. Random effects regression was used to model QTcF longitudinally over 24 weeks and causal frameworks guided the analysis of non-randomized independent variables. 328 participants were included in BPaL-based arms. The longitudinal analysis of investigational arms showed an initial QTcF steep increase in the first week. QTcF trajectories between weeks 2 and 24 differed slightly by regimen, with highest mean peak for BPaLC (QTcF 446.5 ms). Overall, there were 397 QTcF >450 ms (of 3,744) and only one QTcF >500 ms. The odds of QTcF >450 ms among participants in any investigational arm, was 8.33 times higher in Uzbekistan compared to Belarus (95% confidence interval: 3.25-21.33). No effect on QTcF prolongation was found for baseline age or body mass index (BMI). Clinically significant QTc prolongation was rare in this cohort of closely monitored participants. Across BPaL-based regimens, BPaLC showed a slightly longer and sustained effect on QTcF prolongation, but the differences (both in magnitude of change and trajectory over time) were clinically unimportant. The disparity in the risk of QTc prolongation across countries would be an important factor to further investigate when evaluating monitoring strategies. CLINICAL TRIALS: This study is registered with ClinicalTrials.gov as NCT02589782.
Assuntos
Antituberculosos , Eletrocardiografia , Síndrome do QT Longo , Moxifloxacina , Rifampina , Humanos , Rifampina/uso terapêutico , Rifampina/efeitos adversos , Masculino , Adulto , Feminino , Moxifloxacina/uso terapêutico , Moxifloxacina/efeitos adversos , Antituberculosos/efeitos adversos , Antituberculosos/uso terapêutico , Síndrome do QT Longo/induzido quimicamente , Pessoa de Meia-Idade , Tuberculose Resistente a Múltiplos Medicamentos/tratamento farmacológico , África do Sul , Clofazimina/uso terapêutico , Clofazimina/efeitos adversos , Diarilquinolinas/uso terapêutico , Diarilquinolinas/efeitos adversos , República de BelarusAssuntos
Clofazimina , Humanos , Clofazimina/efeitos adversos , Clofazimina/administração & dosagem , Feminino , Pigmentação da Pele/efeitos dos fármacos , Masculino , Hiperpigmentação/induzido quimicamente , Hansenostáticos/efeitos adversos , Hansenostáticos/administração & dosagem , Adulto , Pessoa de Meia-IdadeRESUMO
Combined immune checkpoint blockade (ICB) for cancer exhibits good efficacy in a subset of patients but also associates with immune-related adverse events. Xue et al. use an elegant drug screening strategy to identify the antimicrobial drug clofazimine as an agent that both potentiates ICB efficacy and decreases immune-related adverse events.
Assuntos
Clofazimina , Imunoterapia , Neoplasias , Clofazimina/uso terapêutico , Clofazimina/efeitos adversos , Humanos , Imunoterapia/métodos , Imunoterapia/efeitos adversos , Neoplasias/tratamento farmacológico , Neoplasias/imunologia , Inibidores de Checkpoint Imunológico/efeitos adversos , AnimaisRESUMO
OBJECTIVES: Cutaneous hyperpigmentation is one of the main adverse effects encountered in patients undergoing leprosy treatment with multidrug therapy (WHO-MDT). This adverse effect has been described as intolerable and capable of contributing to social stigma. The objectives of this study were to quantify the variation in skin colour induced by clofazimine during and after treatment and to assess the related stigma. METHODS: This observational cross-sectional study objectively measured skin colour in 51 patients by reading the individual typology angle (ITA°) with a spectrophotometer, followed by the application of the Stigma Scale of the Explanatory Model Interview Catalogue (EMIC). RESULTS: Skin hyperpigmentation was observed in 100% of the individuals. They showed more negative ITA° values in lesion areas than non-lesion areas, particularly in sun-exposed regions. Clofazimine-induced cutaneous hyperpigmentation was not homogeneous and seemed to follow the lesion locations. The mean EMIC score was 18.8 points. CONCLUSION: All patients presented skin hyperpigmentation caused by clofazimine, detectable through spectrophotometry. Hyperpigmentation strongly impacted the social domain, indicating the intersectionality of disease and skin colour stigma, contributing to the social isolation of these patients. Health authorities should consider the negative impact of clofazimine on treatment adherence.
Assuntos
Hiperpigmentação , Hanseníase , Humanos , Clofazimina/efeitos adversos , Hansenostáticos/efeitos adversos , Estudos Transversais , Estigma Social , Quimioterapia Combinada , Hanseníase/tratamento farmacológico , Hanseníase/etiologia , Hiperpigmentação/induzido quimicamente , Hiperpigmentação/tratamento farmacológico , Hiperpigmentação/patologiaAssuntos
Clofazimina , Humanos , Clofazimina/efeitos adversos , Masculino , Feminino , Pessoa de Meia-IdadeRESUMO
Leprosy is a global health issue, causing long-term functional morbidity and stigma. Rapid diagnosis and appropriate treatment are important; however, early diagnosis is often challenging, especially in nonendemic areas. Here, we report a case of borderline lepromatous leprosy accompanied by dapsone-induced (neutropenia, anemia, and methemoglobinemia) and clofazimine-induced (skin discoloration and ichthyosis) side effects and type 1 leprosy reactions during administration of the multidrug therapy. The patient completely recovered without developing any deformities or visual impairment. To ensure early diagnosis and a favorable outcome, clinicians should be aware of the diminished sensation of skin lesions as a key physical finding and manage the drug toxicities and leprosy reactions appropriately in patients on multidrug therapy.
Assuntos
Hipersensibilidade , Hanseníase Dimorfa , Hanseníase Virchowiana , Hanseníase Multibacilar , Hanseníase , Doenças do Sistema Nervoso Periférico , Dermatopatias Bacterianas , Humanos , Clofazimina/efeitos adversos , Dapsona/efeitos adversos , Quimioterapia Combinada , Hansenostáticos/efeitos adversos , Hanseníase/patologia , Hanseníase Dimorfa/diagnóstico , Hanseníase Dimorfa/tratamento farmacológico , Doenças do Sistema Nervoso Periférico/tratamento farmacológico , Hanseníase Multibacilar/tratamento farmacológico , Hanseníase Virchowiana/diagnóstico , Hanseníase Virchowiana/tratamento farmacológico , Hanseníase Virchowiana/patologiaRESUMO
Clofazimine is recommended for the treatment of rifampicin-resistant tuberculosis (RR-TB), but there is currently no verified dosing guideline for its use in children. There is only limited safety and no pharmacokinetic (PK) data available for children. We aimed to characterize clofazimine PK and its relationship with QT-interval prolongation in children. An observational cohort study of South African children <18 years old routinely treated for RR-TB with a clofazimine-containing regimen was analyzed. Clofazimine 100 mg gelatin capsules were given orally once daily (≥20 kg body weight), every second day (10 to <20 kg), or thrice weekly (<10 kg). PK sampling and electrocardiograms were completed pre-dose and at 1, 4, and 10 hours post-dose, and the population PK and Fridericia-corrected QT (QTcF) interval prolongation were characterized. Fifty-four children contributed both PK and QTcF data, with a median age (2.5th-97.5th centiles) of 3.3 (0.5-15.6) years; five children were living with HIV. Weekly area under the time-concentration curve at steady state was 79.1 (15.0-271) mg.h/L compared to an adult target of 60.9 (56.0-66.6) mg.h/L. Children living with HIV had four times higher clearance compared to those without. No child had a QTcF ≥500 ms. A linear concentration-QTcF relationship was found, with a drug effect of 0.05 (0.027, 0.075) ms/µg/L. In some of the first PK data in children, we found clofazimine exposure using an off-label dosing strategy was higher in children versus adults. Clofazimine concentrations were associated with an increase in QTcF, but severe prolongation was not observed. More data are required to inform dosing strategies in children.
Assuntos
Clofazimina , Tuberculose Resistente a Múltiplos Medicamentos , Adolescente , Criança , Pré-Escolar , Humanos , Clofazimina/efeitos adversos , Clofazimina/farmacocinética , Infecções por HIV/tratamento farmacológico , Rifampina/farmacologia , Tuberculose Resistente a Múltiplos Medicamentos/tratamento farmacológicoRESUMO
Introdução: O diagnóstico da hanseníase possui números significativos que causam preocupação à saúde pública. Os casos de resistência medicamentosa nessa doença se iniciaram em meados dos anos 60 e diante do problema, a Organização Mundial da Saúde instituiu em 1981 a poliquimioterapia, associação dos antibióticos rifampicina, dapsona e clofazimina, tratamento atual de escolha. A resistência aos fármacos na hanseníase é reportada pela literatura, desvelando um obstáculo à sua eliminação. Apresentamos nessa revisão os principais aspectos da resistência medicamentosa no tratamento para hanseníase e seus impactos. Metodologia: Revisão sistemática sobre os aspectos da resistência medicamentosa utilizando a pesquisa exploratória como metodologia de abordagem. Foram pesquisados os termos resistência medicamentosa, hanseníase, recidiva, alterações genéticas e os operadores booleanos "and" e "or" na busca. Resultados e discussão: A dificuldade de tomar a medicação corretamente foi um dos principais fatores que acarretaram resistência do bacilo Mycobacterium leprae aos fármacos. Homens de países norte e sul-americanos e asiáticos foram os mais atingidos por episódios de resistência. A resistência medicamentosa é uma das principais causas de recidivas em hanseníase. O principal fármaco causador de resistência medicamentosa descrito nos trabalhos foi a dapsona (46,6%) e a maioria das alterações genéticas encontradas estão no gene rpoB; 23,2% dos registros relatados foram de resistência secundária aos fármacos e, também, sete casos de resistência múltipla a esses medicamentos. Conclusão: Os principais aspectos da resistência medicamentosa na hanseníase são os equívocos ao ingerir os medicamentos e as alterações genéticas na bactéria. Os impactos causados estão na dificuldade de refazer o tratamento, a possibilidade de nova transmissão e o aparecimento de sintomas mais graves.
Introduction: The diagnosis of leprosy has significant numbers causing public health concern. Reports of drug resistance in this disease begun in the mid-1960s and due to this problem, the World Health Organization instituted a multidrug therapy with rifampicin, dapsone, and clofazimine antibiotic association in 1981, which is currently the first-choice treatment for leprosy. Cases of drug resistance have been reported in literature, revealing an obstacle to the eradication of the disease. This paper has the purpose of presenting the key aspects and impacts of drug resistance in the treatment for leprosy. Methods: Systematic review of the drug resistance aspects using exploratory research as an approach methodology. The authors searched the terms drug resistance, leprosy, recurrence, genetic alterations, and the Boolean operators "and" and "or" between them. Results and discussion: The difficulty in taking the medication correctly was one of the key factors that led to drug resistance for Mycobacterium leprae. Men from North and South American, as well as from Asian countries, were the most affected by episodes of resistance. Drug resistance is one of the main causes of leprosy recurrences. Dapsone was the most frequently identified drug resistance in the studies (46.6%), while most of the genetic alterations were found in the rpoB gene; 23.2% of the cases were from secondary resistance episodes, and seven cases of multiple resistance were reported. Conclusion: The misconceptions when taking the treatment and the Mycobacterium leprae genetic alterations have been described as the key aspects of drugs resistance in leprosy and the impacts caused are the difficulty in redoing the treatment, the possibility of new transmission, and the appearance of more severe symptoms.
Assuntos
Resistência a Medicamentos/efeitos dos fármacos , Farmacorresistência Bacteriana/efeitos dos fármacos , Mycobacterium leprae/efeitos dos fármacos , Rifampina/efeitos adversos , Bactérias/genética , Preparações Farmacêuticas , Clofazimina/efeitos adversos , Fluoroquinolonas/efeitos adversos , Dapsona/efeitos adversos , Quimioterapia Combinada/efeitos adversos , Hanseníase/tratamento farmacológico , Antibacterianos/efeitos adversosRESUMO
Abstract: BACKGROUND: The Clinical Trial for Uniform Multidrug Therapy for Leprosy Patients in Brazil (U-MDT/CT-BR), designed to evaluate the effectiveness of a six-months regimen, assessed the adverse effects caused by the drugs. OBJECTIVE: Describe adverse effects due to MDT in U-MDT/CT-BR, comparing the uniform regimen (U-MDT) to the current WHO regimen (R-MDT). Patients and methods: After operational classification, patients were randomly allocated to the study groups. U-MDT PB and U-MDT MB groups, received the U-MDT regimen, six doses of MB-MDT (rifampicin, dapsone and clofazimine). R-MDT PB and R-MDT MB groups, received the WHO regimens: six doses (rifampicin and dapsone) for PB and 12 doses (rifampicin, dapsone and clofazimine) for MB. During treatment, patients returned monthly for clinical and laboratorial evaluation. Patients with single lesion were not included in this trial. RESULTS: Skin pigmentation (21.7%) and xerosis (16.9%) were the most frequent complaints among 753 patients. Laboratory exams showed hemoglobin concentration lower than 10g/dL in 23.3% of the patients, glutamic oxaloacetic transaminase (GOT) above 40U/L in 29.5% and glutamic pyruvic transaminase (GPT) above 40U/L in 28.5%. Twenty-four patients (3.2%) stopped dapsone intake due to adverse effects, of whom 16.6% due to severe anemia. One case of sulfone syndrome was reported. STUDY LIMITATIONS: Loss of some monthly laboratory sample collection. CONCLUSIONS: There was no statistical difference regarding adverse effects in the R-MDT and U-MDT groups but anemia was greater in patients from R-MDT/MB group, therefore adverse effects do not represent a constraint to recommend the six-month uniform regimen of treatment for all leprosy patients.
Assuntos
Humanos , Masculino , Feminino , Criança , Adolescente , Adulto , Pessoa de Meia-Idade , Adulto Jovem , Rifampina/efeitos adversos , Clofazimina/efeitos adversos , Dapsona/efeitos adversos , Hansenostáticos/efeitos adversos , Rifampina/administração & dosagem , Brasil , Hemoglobinas/análise , Fatores de Risco , Resultado do Tratamento , Clofazimina/administração & dosagem , Dapsona/administração & dosagem , Quimioterapia Combinada/efeitos adversos , Anemia/induzido quimicamente , Anemia/sangue , Hansenostáticos/administração & dosagem , Hanseníase/complicações , Hanseníase/tratamento farmacológico , Hanseníase/sangueRESUMO
La lepra es una infección crónica, granulomatosa, producida por Mycobacterium leprae, que afecta piel y nervios periféricos. Se describen dos tipos de reacciones leprosas: tipo I y tipo II, las que corresponden a cuadros agudos que exacerban la enfermedad. Estas leproreacciones pueden ocurrir antes, durante o después del tratamiento. Se presenta el caso de un paciente masculino que acude a consultar con lesiones cutáneas y resultado de biopsia de piel con diagnóstico de lepra. Se inicia tratamiento multidroga OMS-MB1. Posteriormente presenta una leproreacción tipo I, por lo que se le realiza tratamiento con prednisona.
Leprosy is a chronic granulomatous infection of the skin and peripheral nervous system produced by Mycobacterium leprae. Two types of acute leprosy reactions have been described: type I and type II. These reactions can occur before, during or after treatment. We present the case of an adult male patient presenting with skin lesions and skin biopsy diagnostic for leprosy. A multidrug WHO-MB 1 treatment was initiated, after which he presents with type I lepra reaction requiring corticosteroids.
Assuntos
Humanos , Masculino , Pessoa de Meia-Idade , Hanseníase Virchowiana/diagnóstico , Hanseníase Virchowiana/tratamento farmacológico , Clofazimina/efeitos adversos , Quimioterapia Combinada/efeitos adversos , Eritema Nodoso/induzido quimicamente , Rifampina/efeitos adversos , Biópsia , Dapsona/efeitos adversos , Hanseníase Multibacilar/patologia , Hansenostáticos/efeitos adversosAssuntos
Humanos , Clofazimina/uso terapêutico , Dapsona/uso terapêutico , Diagnóstico Clínico , Hanseníase Multibacilar/tratamento farmacológico , Hanseníase Paucibacilar/tratamento farmacológico , Hanseníase/diagnóstico , Minociclina/uso terapêutico , Ofloxacino/uso terapêutico , Rifampina/uso terapêutico , Centros de Saúde , Clofazimina/efeitos adversos , Dapsona/efeitos adversos , Minociclina/efeitos adversos , Ofloxacino/efeitos adversos , Quimioterapia Combinada , Rifampina/efeitos adversos , Técnicas e Procedimentos DiagnósticosRESUMO
BACKGROUND: After the introduction of the multidrug therapy, there was a decline in the coefficients of prevalence and detection of new cases of leprosy. However, the records of drug resistance and relapses are threatening factors in leprosy control. Hence, new alternative schemes and monitoring of adverse effects to avoid treatment abandonment are important considerations. OBJECTIVE: Describe the side effects of a multidrug regimen containing minocycline, ofloxacin, and clofazimine in multibacillary leprosy patients. METHODS: We conducted a prospective, descriptive, and observational study with multibacillary patients, including cases of intolerance to standard MDT and relapses. The study was carried out at Fundação Alfredo da Matta (Alfredo da Matta Foundation), in Manaus, Amazonas, from April 2010 to January 2012. The patients received alternative therapy, which consisted of daily self-administered doses of 100mg of minocycline, 400 mg of ofloxacin, and 50mg of clofazimine and a supervised monthly dose of 300mg of clofazimine for six months, followed by eighteen months of daily doses of ofloxacin 400mg, clofazimine 50mg, and a supervised monthly dose of clofazimine 300mg. Results: Twenty-one cases were included. Mild and transitory side effects occurred in 33.3% of patients. Of the total episodes, 45.9% were attributed to ofloxacin and they included abdominal pain, nausea, vomiting, headache, and insomnia; 21.6% were due to clofazimine, with 100% of patients presenting skin pigmentation. The mean time for the development of adverse effects after beginning the therapy was 15.2 days. CONCLUSION: All patients tolerated the drugs well, and compliance was satisfactory, with no serious events. Unlike other standard MDT studies ...
FUNDAMENTOS: Após introdução do esquema poliquimioterápico padrão, houve declínio nos coeficientes de prevalência e detecção de casos novos; entretanto, os registros de resistência medicamentosa e recidivas representam ameaça para o controle da hanseníase. Dessa forma, a proposição de novos esquemas alternativos e a necessidade de monitorar efeitos adversos são importantes para evitar o abandono do tratamento. OBJETIVO: Descrever efeitos adversos do esquema alternativo contendo clofazimina, ofloxacina e minociclina em pacientes com hanseníase multibacilar. MÉTODOS: Estudo prospectivo, descritivo e observacional de casos multibacilares, incluindo recidivas ou intolerância à poliquimioterapia padrão, realizado na Fundação Alfredo da Matta, Manaus, Amazonas, de abril de 2010 a janeiro de 2012. Os indivíduos receberam a terapia composta de doses diárias auto-administradas de 100mg de minociclina, 400mg de ofloxacina e 50mg de clofazimina e mensais supervisionadas de 300mg de clofazimina por seis meses, seguidas de 18 meses de doses diárias de ofloxacina 400mg, clofazimina 50 mg e supervisionadas mensais de clofazimina 300mg. Resultados: 21 pacientes foram incluídos. Efeitos adversos leves e transitórios foram observados em 33,3% dos pacientes; 45,9% foram atribuídos à ofloxacina, como dor abdominal, náuseas, vômitos, cefaléia e insônia; 21,6% foram associados à clofazimina, com relatos e observação em 100% dos pacientes de hiperpigmentação cutânea. O tempo médio de desenvolvimento das reações adversas a partir do início do esquema foi de 15,2 dias. ...
Assuntos
Adolescente , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem , Clofazimina/efeitos adversos , Hansenostáticos/administração & dosagem , Hanseníase Multibacilar/tratamento farmacológico , Minociclina/efeitos adversos , Ofloxacino/efeitos adversos , Brasil , Clofazimina/administração & dosagem , Quimioterapia Combinada/efeitos adversos , Quimioterapia Combinada/métodos , Minociclina/administração & dosagem , Ofloxacino/administração & dosagem , Estatísticas não Paramétricas , Fatores de Tempo , Resultado do TratamentoAssuntos
Hanseníase/tratamento farmacológico , Antidepressivos Tricíclicos/efeitos adversos , Carbamazepina/efeitos adversos , Clofazimina/efeitos adversos , Corticosteroides/efeitos adversos , Minociclina/efeitos adversos , Ofloxacino/efeitos adversos , Pentoxifilina/efeitos adversos , Rifampina/efeitos adversos , Sulfonas/efeitos adversos , Talidomida/efeitos adversosRESUMO
This study sought to verify the correlation between leprosy types and the adverse effects of treatment drugs. This quantitative, prospective, nested study was developed at the Dona Libânia Dermatology Centre in Fortaleza, Brazil. Data were collected from November 2007-November 2008. During this period, 818 leprosy patients were diagnosed and began treatment. Forty patients with tuberculoid leprosy (TT) were selected. Twenty patients followed a standard therapy of dapsone and rifampicin and 20 were administered dapsone, rifampicin and clofazimine (U-MDT). Twenty patients with borderline lepromatous (BL) and lepromatous leprosy (LL) were also selected and treated with U-MDT. All of the subjects received six doses. With the exception of haemolytic anaemia, there was a low incidence of adverse effects in all the groups. We did not observe any differences in the incidence of haemolytic anaemia or other side effects across groups of patients with TT, BL or LL treated with U-MDT.
Assuntos
Adolescente , Adulto , Idoso , Criança , Humanos , Pessoa de Meia-Idade , Adulto Jovem , Hansenostáticos/administração & dosagem , Hanseníase Virchowiana/tratamento farmacológico , Hanseníase Multibacilar/tratamento farmacológico , Hanseníase Tuberculoide/tratamento farmacológico , Clofazimina/administração & dosagem , Clofazimina/efeitos adversos , Quimioterapia Combinada , Dapsona/administração & dosagem , Dapsona/efeitos adversos , Hansenostáticos/efeitos adversos , Estudos Prospectivos , Rifampina/administração & dosagem , Rifampina/efeitos adversosRESUMO
INTRODUÇÃO: A hanseníase é uma doença infecto contagiosa crônica, causada pelo Mycobacterium leprae, enão foi exterminada no Brasil, que atualmente, ocupa o segundo lugar em número absoluto de casos, perdendoapenas para a Índia. A doença hanseníase não provoca estresse oxidativo, e sim a terapêutica utilizada. Diversos trabalhos evidenciam a redução do estresse oxidativo, em diferentes patologias, pelo uso da vitamina E. Na hanseníase, no entanto, a literatura é escassa a respeito desse efeito OBJETIVO: O objetivo deste estudo foi verificar a redução, pela vitamina E, do estresse oxidativo causado pelo uso da dapsona, clofazimina e rifampicina no tratamento pacientes hansenianos, da forma multibacilar. CASUÍSTICA E MÉTODO: Foi avaliada a presença prévia de estresse oxidativo em 32 pacientes hansenianos, da forma multibacilar, por meio de exames de sangue e, posteriormente, os pacientes foram divididos em 2 grupos, aleatoriamente, com 16 pacientes em cada grupo,denominados: grupos com vitamina E e controle. Os pacientes do grupo com vitamina E fizeram uso de800 UI/dia, por via oral, de vitamina E e o grupo controle não fez uso de suplemento vitamínico. Decorridos30, 60 e 90 dias de tratamento suplementar, foram coletadasamostras de sangue dos 2 grupos para determinar a concentração de metahemoglobina e presença de corpos de Heinz. RESULTADOS: Os resultados foram submetidos ao testeestatístico Qui-quadrado (χ2). Não foi encontrada diferença entre os 2 grupos.CONCLUSÃO: Conclui-se que a vitamina E na dose e duração de tratamentos utilizados, não confere efeitoprotetor contra o estresse oxidativo causado pela dapsona, clofazimina e rifampicina utilizada pelos pacientesportadores de hanseníase da forma multibacilar.
INTRODUCTION: Leprosy is a chronic contagious infectious disease caused by Mycobacterium leprae, and has not been wiped out in Brazil, which currently ranks second in the absolute number of cases, second only to India. The disease is not leprosy causes oxidative stress, but the therapy used. Several studies show the reductionof oxidative stress in different pathology, the use of vitamin E. In leprosy, however, the literature is scarce about this effect. OBJECTIVE: The aim of this study was the reduction by vitamin E, oxidative stress caused by the use of dapsone, rifampicin and clofazimine for treating leprosy patients, the multibacillary form.PATIENTS AND METHODS: We reviewed the previous presence of oxidative stress in 32 leprosy patients, themultibacillary form, through blood tests and then the patients were divided into two groups randomly, with 16 patients in each group, namely: groups with vitamin E and control . Patients in the group with vitamin E made use of 800 IU / day orally, vitamin E and control group did not use vitamin supplement. After 30, 60 and 90 days of treatment, blood samples were collected from two groups to determine the concentration of methemoglobin and the presence of Heinz bodies.RESULTS: The results were subjected to statistical test Chi-square (χ2). No difference was found between thetwo groups. CONCLUSION: We conclude that vitamin E dose and durationof treatments, does not confer a protective effect against oxidative stress caused by dapsone, rifampicinand clofazimine used by patients with multibacillary leprosy.
Assuntos
Humanos , Clofazimina/efeitos adversos , Clofazimina/uso terapêutico , Dapsona/efeitos adversos , Dapsona/uso terapêutico , Estresse Oxidativo , Hanseníase Multibacilar/tratamento farmacológico , Rifampina/efeitos adversos , Rifampina/uso terapêutico , Vitamina E/uso terapêutico , Distribuição de Qui-Quadrado , Efeitos Colaterais e Reações Adversas Relacionados a MedicamentosRESUMO
Multidrug therapy (WHO/MDT) in multibacillary leprosy consists of treatment with rifampicin, dapsone andclofazimine. However, adverse effects can cause the patient to abandon treatment. We report on a patient whopresented agranulocytosis and hemolytic anemia associated with this treatment regime. We also examined theimportance of laboratory exams for diagnosis and follow-up of the patient, and for early detection of adverse effects, with a view to improving adhesion to treatment and contributing to the eradication of Hansens disease as a public health issue.
Assuntos
Adulto , Feminino , Humanos , Agranulocitose/induzido quimicamente , Anemia Hemolítica/induzido quimicamente , Hansenostáticos/efeitos adversos , Clofazimina/efeitos adversos , Dapsona/efeitos adversos , Quimioterapia Combinada/efeitos adversos , Hanseníase/tratamento farmacológico , Rifampina/efeitos adversosRESUMO
A implementaçäo da poliquimioterapia (PQT/OMS) - composta pelas drogas dapsona, clofazimina e rifampicina - possibilitou a cura da hanseníase, porém näo foram priorizados o manejo dos efeitos adversos pelas equipes de saúde. Objetivando determinar a magnitude dos efeitos adversos da poliquimioterapia para hanseníase e relacioná-los como possível causa de näo adesividade do paciente ao tratamento, revisou-se prontuários de 187 pacientes tratados com PQT, de 1995 a 2000, no Centro de Saúde Escola (CSE) -UFU, com registro de efeitos colaterais em 71 pacientes (37,9 por cento). Dentre os 113 efeitos adversos, 80 (70,7 por cento) relacionaram-se à dapsona, 7 (6,2 por cento) à rifampicina, 26 (20,5 por cento) à clofazimina. Esses efeitos levaram à mudança de esquema terapêutico em 28 (14,9 por cento) dos 187 pacientes ou 39,4 por cento dos 71 com efeitos adversos. Discute-se a importância de considerar os efeitos adversos da PQT na capacitaçäo das equipes de saúde para maior adesäo do paciente ao tratamento, colaborando para eliminar a hanseníase como problema de saúde pública
Assuntos
Adolescente , Adulto , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Recém-Nascido , Masculino , Pessoa de Meia-Idade , Clofazimina/efeitos adversos , Dapsona/efeitos adversos , Hansenostáticos/efeitos adversos , Hanseníase/tratamento farmacológico , Rifampina/efeitos adversos , Clofazimina/administração & dosagem , Quimioterapia Combinada , Dapsona/administração & dosagem , Hansenostáticos/administração & dosagem , Cooperação do Paciente/estatística & dados numéricos , Pacientes Desistentes do Tratamento/estatística & dados numéricos , Estudos Retrospectivos , Rifampina/administração & dosagemRESUMO
The introduction of multidrug therapy (WHO/MDT)-composed by the drugs dapsone, clofazimine and rifampicin has enabled the cure of Hansen's disease, however, the adverse effects of these drugs were not given priority by the health team. Aiming to determine MDT's adverse effects' magnitude and relate them to the non-adhesion of patients to the treatment, a study of 187 charts of patients treated with MDT from January of 1995 to May 2000, was carried out at a Health Center of the Federal University of Uberlandia. Side effects were recorded in 71 patients' charts. Among the 113 side effects found, 80 (70.7 per cent) were related to dapsone, 7 (6.2 per cent) were caused by rifampicin and 26 (20.5 per cent) were attributed to clofazimine. These effects induced 28 (14.9 per cent), patients to change the therapeutic scheme, representing 39.4 per cent from the 71 patients with adverse effects. Throughout this study, the importance is discussed of considering MDT's adverse effects when training the health team to heighten the patient's adhesion to the treatment and thereby collaborating to eliminate Hansen's disease as a public health problem.
Assuntos
Feminino , Masculino , Pré-Escolar , Criança , Adulto , Humanos , Lactente , Recém-Nascido , Pessoa de Meia-Idade , Clofazimina/administração & dosagem , Clofazimina/efeitos adversos , Cooperação do Paciente/estatística & dados numéricos , Dapsona/administração & dosagem , Dapsona/efeitos adversos , Estudos Retrospectivos , Hansenostáticos/administração & dosagem , Hansenostáticos/efeitos adversos , Hanseníase/tratamento farmacológico , Pacientes Desistentes do Tratamento/estatística & dados numéricos , Quimioterapia Combinada , Rifampina/administração & dosagem , Rifampina/efeitos adversosRESUMO
Gastrointestinal toxicity and red skin discoloration were the major side effects observed in leprosy patients undergoing long-term treatment with clofazimine (CFZ). Hematological and biochemical alterations have been cited among other side effects; however, their real magnitude and clinical significance at the doses currently employed in therapy have not been sufficiently documented. We therefore investigated the correlation between CFZ plasma concentration and biochemical (transaminases, bilirubins, alkaline phosphatase, gamma-glutamyltransferase, amylase, urea, creatinine, and potassium plasma levels) as well as hematological changes blood and reticulocyte counts, osmotic fragility, detection of Heinz bodies and methemoglobinemia (MHM), following in two regimes of treatment: CFZ as a single drug and CFZ as part of multidrug (MDT) therapy, in combination with dapsone and rifampicin. MHM and hemolytic anemia were detected in the MDT group only. Eosinophilia was found in patients of either group. Determination of hepatic, pancreatic and renal biochemical parameters showed rare, occasional changes of apparently no clinical significance. We conclude that CFZ is a generally well tolerated and safe drug when given as a daily dose of 50mg, which is currently used in leprosy patients.